Sin conexión a internet: se muestra la versión guardada de la página.

Heron Therapeuti

USUSD
← Al Screener

Heron Therapeuti (LSE:0J4V) — Biotechnology: Pharmaceutical Preparations. Número de bolsas en las que cotizan las acciones de la empresa: 2. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.

Sobre la Empresa

Sitio Web
herontx.com
Relaciones con los Inversores
ir.herontx.com/
Sector
Health Care · Biotechnology: Pharmaceutical Preparations
Sede Central
SAN DIEGO, United States
Consejero Delegado
Craig Alexander Collard
Empleados
128
Cotiza Desde
29.01.2018 (LSE:0J4V)
Acciones en Circulación
189.85 M a 2026-08-05
Capital Flotante
146.52 M
Capitalización Bursátil
77.1 M USD
Insiders
0.98%
Inversores Institucionales
70.98%
Industria (SIC)
Pharmaceutical Preparations
P/E
pérdidas
FCF
−12.1 M USD
Deuda
64.0 mil USD
caja neta
Resultados y FCF — para los 12 meses hasta 30.06.2026 (el último informe de la empresa).
NAV
0.04 USD · P/NAV 10.0
Balance sheet date30.06.2026
Assets252 M USD
− Liabilities245 M USD
= NAV (equity of the company's shareholders)6.91 M USD
= Tangible NAV6.91 M USD
Acciones189 852 307
NAV per share0.04 USD
NAV Tangible por Acción0.04 USD
Share price (0J4V)0.3653 USD
P/NAV10.04
NAV history
Balance sheet dateNAVNAV per share
30.06.20266.91 M USD0.04 USD
31.03.20269.14 M USD0.05 USD
31.12.202514.3 M USD0.08 USD
30.09.202514.9 M USD0.08 USD
30.06.2025−27.3 M USD−0.18 USD
31.03.2025−28.5 M USD−0.19 USD
31.12.2024−33.7 M USD−0.22 USD
30.09.2024−40.0 M USD−0.26 USD
Descripción

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.

anuncio

Bolsas y Tickers

BolsaTickerMonedaPrecioTipo
US USA StocksHRTX principalUSD0.362 -7.32%acciones ordinarias
LSE London Stock Exchange0J4V IOBUSD0.3653 +0.00%acciones ordinarias

Precio en 3 Meses

día alcista día bajistaPasa el cursor / toca un día — precios de apertura, cierre, máximo y mínimo

Principales Accionistas

TitularParticipaciónAccionesFecha del Informe
Rubric Capital Managemen…15.83%30.05 M2026-06-30
Clearline Capital, LP6%11.38 M2026-06-30
Blackrock Inc.5.56%10.55 M2026-06-30
MORGAN ADAM (Director)≈4.68%8.88 M2026-01-30
Velan Capital Investment…4.61%8.75 M2026-06-30
Vanguard Capital Managem…4.1%7.78 M2026-06-30
Tejara Capital Ltd3.43%6.51 M2026-06-30
Tang Capital Management,…3.29%6.25 M2026-06-30
VANGUARD INDEX FUNDS-Van…2.88%5.47 M2026-06-30
Geode Capital Management…2.25%4.27 M2026-06-30
Millennium Management Ll…2.14%4.07 M2026-06-30
JW Asset Management, LLC1.98%3.75 M2026-06-30
iShares Trust-iShares Ru…1.91%3.63 M2026-08-31
VANGUARD INDEX FUNDS-Van…1.09%2.06 M2026-06-30
Fidelity Salem Street Tr…0.86%1.63 M2026-07-31
iShares Trust-iShares Ru…0.72%1.37 M2026-08-31
SCHWAB STRATEGIC TRUST-S…0.46%869 9042026-05-31
COLLARD CRAIG ALEXANDER…≈0.45%856 4922026-07-31
VANGUARD SCOTTSDALE FUND…0.41%783 9922026-05-31
Fidelity Concord Street…0.33%635 7122026-07-31
iShares Trust-iShares Mi…0.28%533 8002026-08-31
iShares Trust-iShares Ru…0.27%504 9822026-08-31
DUARTE IRA (Chief Financ…≈0.15%281 8992026-07-31
FORBES WILLIAM P (Office…≈0.13%241 1732026-07-31
HENSLEY MARK EARL (Chief…≈0.09%170 9012026-08-06
RODRIGUEZ SUSAN (Directo…≈0.05%87 1802025-01-31
CUSACK THOMAS J (Directo…≈0.03%53 9602026-01-30
JOHNSON CRAIG A (Directo…≈0.03%53 9602026-01-30
KASETA MICHAEL (Director…≈0.03%53 9602026-01-30
RUBRIC CAPITAL MANAGEMEN…——2025-10-15